Innovating.works Conecta tu I+D

ReModel-OP: Identifying strategies to reduce osteoporosis-driven bone loss through the development of microphysi... BRIGHAM INC participó en un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Osteoporosis is a common skeletal disorder characterized by imbalanced bone remodeling, where osteoclast activity is exacerbated leading to...
2024-05-13 - 2028-03-16 | Financiado

VoluFaTE: VoluFaTE: Volumetric programming of cells to control the fate and function of engineered tissues BRIGHAM INC participó en un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Engineering living tissues is expected to revolutionize pharmacological screenings, fundamental biological studies, cruelty-free meat produc...
2023-03-08 - 2026-09-14 | Financiado

CLOCKrisk: Targeting the circadian clock in personalized disease prevention Virtually every cell of our body follows the 24-hr ‘circadian’ rhythm of a hypothalamic master pacemaker that evolved in the natural light-d...
2022-09-27 - 2027-09-30 | Financiado

Th17 tissue metab: Metabolic imprinting of Th17 cells in disease pathogenesis BRIGHAM INC participó en un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 Autoimmune diseases affect an estimated 3-9% of the population and cause major personal and socio-economic consequences. IL-17-producing CD4...
2022-06-26 - 2025-08-31 | Financiado

MACROVALVE: Understanding the role of macrophages in the structural degeneration of bioprosthetic heart valve le... BRIGHAM INC participó en un H2020: H2020-MSCA-IF-2020 Heart valve disease is predicted to be the next cardiac epidemic. Valve prostheses used to treat this disease are comprised of biological ti...
2021-03-19 - 2025-08-31 | Financiado

BrainChip4MED: Brain on a chip as a preclinical model tool for the screening of theranostic nanoformulations for ne... BRIGHAM INC participó en un H2020: H2020-MSCA-IF-2020 Despite all the progress and effort that has been made in the last few decades regarding the research on neurodegenerative diseases, the com...
2021-03-13 - 2024-02-29 | Financiado

DynChan: Dynamic regulation of paracellular channel gating BRIGHAM INC participó en un H2020: H2020-MSCA-IF-2019 Epithelial paracellular, i.e., tight junction, permeability is largely defined by the integrated functions of claudin proteins that can eith...
2020-04-01 - 2024-03-15 | Financiado

STOPFOP: Saracatinib Trial tO Prevent FOP BRIGHAM INC participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling and life-shortening congenital syndrome for which no effective therapies ex...
2019-04-17 - 2024-10-31 | Financiado

PRINT-CHEMO: To develop 3D bioPRINTed osteoinductive constructs that deliver CHEMOtherapeutics within large bone... BRIGHAM INC participó en un H2020: H2020-MSCA-IF-2018 Osteosarcoma is the most commonly diagnosed bone tumour with most of these cases being in children and adolescents. Each year over 4,000 new...
2019-04-02 - 2022-06-30 | Financiado

DANTE: Use of novel techniques to identify pathogenic versus non pathogenic TH17 cells in experimental auto... BRIGHAM INC participó en un H2020: H2020-MSCA-IF-2015 The aim of this Fellowship is for the researcher, Dr Karen Dixon, to receive advanced training, develop interdisciplinary skills with high-i...
2016-09-01 - 2020-09-29 | Financiado

HOXA9 degradome: Deciphering the machinery involved in stability of the transcription factor HOXA9. BRIGHAM INC participó en un H2020: H2020-MSCA-IF-2015 Transcription factors are often mutated or aberrantly expressed in cancer and drive carcinogenesis. HOXA9 is a master transcription factor t...
2016-03-09 - 2020-09-05 | Financiado

FORCE: Imaging the Force of Cancer BRIGHAM INC participó en un H2020: H2020-PHC-2014-2015 Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its...
2015-12-09 - 2021-07-31 | Financiado

SAFEGUARD: Safety Evaluation of Adverse Reactions in Diabetes BRIGHAM INC participó en un FP7: "In 2010 a widely marketed drug for the treatment of type 2 diabetes (T2DM) (rosiglitazone) was taken from the market as it was associated w...
Financiado

CHANCES: Consortium on Health and Ageing Network of Cohorts in Europe and the United States BRIGHAM INC participó en un FP7: CHANCES aims at combining and integrating on-going cohort studies in order to produce evidence on ageing-related health characteristics and...
Financiado

EPISTOP: Long term prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a ge... BRIGHAM INC participó en un FP7: Despite a great progress in the management of epilepsy, still one third of patients is refractory to available medications. The incidence of...
Financiado

IMMODGEL: Local Immunomodulation around implants by innovative auxiliary hydrogel based systems encapsulating... BRIGHAM INC participó en un FP7: IMMODGEL aims to identify adverse immune reactions to dental and larynx titanium implants and to develop a novel therapeutic strategy to sig...
Financiado